CIK 0001360214 · Large accelerated filer
HARROW, INC.
Sign in to watch- Ticker
- HROW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450567010
- Phone
- 615.733.4731
- Business address
- 1A BURTON HILLS BLVD, SUITE 200, NASHVILLE, TN
- Former names
- HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., TRANSDEL PHARMACEUTICALS INC, Bywater Resources, Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 43 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-14 | Graves Adrienne L Director | Grant or award · RSU | +8,347 | 8,347 | ||
| 2024-06-14 | SILVERNAIL LAUREN P Director | Grant or award · RSU | +8,347 | 8,347 | ||
| 2024-04-25 | Opaleye Management Inc. 10% owner | Purchase | +20,000 | $9.97 | $199K | 3,815,000 |
| 2024-04-24 | Opaleye Management Inc. 10% owner | Purchase | +8,285 | $10.15 | $84K | 3,795,000 |
| 2024-04-23 | Opaleye Management Inc. 10% owner | Purchase | +11,715 | $10.29 | $121K | 3,786,715 |
| 2024-04-19 | Opaleye Management Inc. 10% owner | Purchase | +29,400 | $10.56 | $310K | 3,775,000 |
| 2024-03-28 | Opaleye Management Inc. 10% owner | Purchase | +50,000 | $12.82 | $641K | 3,745,600 |
| 2024-03-22 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Purchase | +9,000 | $11.59 | $104K | 2,137,525 |
| 2024-03-20 | Opaleye Management Inc. 10% owner | Purchase | +50,600 | $9.65 | $488K | 3,695,600 |
| 2024-03-01 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise | +5,000 | $8.75 | $44K | 254,803 |
| 2024-03-01 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise · Stock Option (Right to Buy) | −5,000 | 0 | ||
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise | +30,000 | $10.67 | $320K | 262,419 |
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise | −12,616 | $10.67 | $135K | 249,803 |
| 2024-02-20 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise · RSU | −30,000 | 0 | ||
| 2024-02-20 | BOLL ANDREW R. CHIEF FINANCIAL OFFICER | Option exercise | +45,000 | $10.67 | $480K | 586,569 |
| 2024-02-20 | BOLL ANDREW R. CHIEF FINANCIAL OFFICER | Option exercise | −18,480 | $10.67 | $197K | 568,089 |
| 2024-02-20 | BOLL ANDREW R. CHIEF FINANCIAL OFFICER | Option exercise · RSU | −45,000 | 0 | ||
| 2024-02-20 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Option exercise | +150,000 | $10.67 | $1.6M | 2,188,361 |
| 2024-02-20 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Option exercise | −59,836 | $10.67 | $638K | 2,128,525 |
| 2024-02-20 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Option exercise · RSU | −150,000 | 0 |
Page 4 of 17 · 336 trades